Quick Answer
Anixa Biosciences Inc reported R&D Expense of $5.07 million for fiscal year 2025.
Anixa Biosciences Inc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $5.07M | -20.7% |
| 2024 | $6.40M | +34.1% |
| 2023 | $4.77M | -28.9% |
| 2022 | $6.70M | +8.3% |
| 2021 | $6.19M | +41.3% |
| 2020 | $4.38M | -20.0% |
| 2019 | $5.47M | -19.7% |
| 2018 | $6.81M | +326.5% |
| 2017 | $1.60M | +2.6% |
| 2016 | $1.56M | -29.6% |
| 2012 | $2.21M | -29.2% |
| 2011 | $3.12M | +3.9% |
| 2010 | $3.01M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $1.10M | -29.0% | +4.5% |
| July 31, 2025 | $1.05M | -45.2% | -20.2% |
| April 30, 2025 | $1.32M | -19.7% | -14.8% |
| January 31, 2025 | $1.55M | +15.0% | -19.4% |
| July 31, 2024 | $1.93M | +76.9% | +17.0% |
| April 30, 2024 | $1.65M | +64.9% | +22.0% |
| January 31, 2024 | $1.35M | +26.3% | +24.0% |
| July 31, 2023 | $1.09M | -24.7% | +9.0% |
- Anixa Biosciences Inc showed a decrease of -20.7% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, Anixa Biosciences Inc’s r&d expense has grown by 68.6% (from $3.01 million to $5.07 million).
- The most recent figure is from Anixa Biosciences Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on January 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: